An Observational Study of Dutasteride and Alpha-blocker Combination Therapy in Men With Symptomatic Benign Prostatic Hyperplasia and PSA Level Over 4 ng/mL

Taipei Medical University

Status: Unknown

Conditions: Benign Prostatic Hyperplasia

Study type: Observational

Funder types: Other

Identifiers

NCT01351987

100006

Details and patient eligibility

About

To analyze the change in International Prostate Symptom Score (IPSS) and serum prostate-specific antigen (PSA) level from baseline.

Full description

This is a non-interventional, observational and multicenter study. When subjects will be allowed the dutasteride and α-blocker orally once daily for two years by investigator's prescription. They will be invited to this observational study. All eligible subjects can be allowed the prior alpha blockers therapy. Details of acute urinary retention (AUR) and BPH-related prostatic surgery episodes will be recorded at every visit. Subjects will return to the clinic for assessment every 3 months until week 96. The efficacy and safety of combining the 5α-reductase inhibitor (5ARI), dutasteride, and the α-blocker will be assessed.

Enrollment: 855 estimated patients

Sex: Male

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males, age ≧ 50 years
• Clinical diagnosis of BPH by medical history and physical examination, including a digital rectal examination (DRE)
• IPSS score ≧ 8 points and prostate volume ≧ 30 mL
• Total serum PSA ≧ 4.0 ng/mL and ≦ 20 ng/mL at screening
• Previous TRUS-guided biopsy have been done with benign findings and with prostate cancer (CaP) not detected within the past 6 months.
• Dutasteride combination therapy will be allowed by investigator's prescription
• Ability to understand and willingly provide written informed consent

Exclusion criteria

• History or evidence of prostate cancer and high grade prostatic intraepithelial neoplasia (HGPIN)
• With symptomatic urinary tract or prostate infection or urinary retention within 3 months prior to entry of study
• Use of finasteride within 6 months of screening visit
• Use of dutasteride within 12 months of screening visit